Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo Europe GmbH

European News

Expert report highlights urgent action needed to lessen the future impact of Atrial Fibrillation in Europe

Daiichi Sankyo Master Prize: Award for the Best Graduate in Pharmaceutical Sciences at the University of Munich

Plant Expansion: Daiichi Sankyo Inaugurates New Building for Pharmaceutical Development in Pfaffenhofen, Bavaria

Daiichi Sankyo Receives Approval for Additional Indications of LIXIANA® (edoxaban) in Japan

PREFER in VTE registry reveals new insights into use of Novel Oral Anticoagulants (NOACs) in the treatment and management of venous thromboembolism (VTE)

One year data from the PREFER in AF registry show significant changes in atrial fibrillation (AF) management in Europe and implementation of clinical guidelines

Subgroup Analysis of ENGAGE AF-TIMI 48 Explores the Relationship Between Edoxaban Dose, Concentration, Anti-Factor Xa Activity and Outcomes

Global Survey of Cardiologists Highlights Complexity of Managing Non-Valvular Atrial Fibrillation and Reinforces Need for Individualized Approach to Patient Care